Despite effective screening methods for cervical cancer, many women do not have access or are not screened in a timely manner which results in delayed diagnosis and higher rates of advanced disease with lower survival rates. In recent years, immunotherapy has emerged as a new frontline treatment option that improves outcomes in women with PD-L1 positive advanced cervical cancer. In this activity you will learn about one patient’s journey with advanced cervical cancer, including her symptoms, the importance of biomarker testing, and her experience with immunotherapy.
Upon completion of this activity, participants should be better able to:
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Resources
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources